Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China
Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, Zhu J, Zhang YH, Chen YS, Friesen MD, Jacobson LP, Muñoz A, Ng D, Qian GS, Zhu YR, Chen TY, Botting NP, Zhang Q, Fahey JW, Talalay P, Groopman JD, Kensler TW
Cancer prevention research (Philadelphia, Pa.) · 160 citations
How it was studied
- Design
- Controlled clinical trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- No health outcome
- Intake measured by
- Not stated
Who paid for it
- Funding
- Independent funding
- University or hospital
- Johns Hopkins University
- Government
- National Cancer Institute
- Government
- National Institute of Environmental Health Sciences
- Government
- NIEHS NIH HHS
- Government
- NCI NIH HHS
- Grants
- National Cancer Institute (R01 CA93780); National Institute of Environmental Health Sciences (P30 ES 003819); National Institute of Environmental Health Sciences (ES003819); National Institute of Environmental Health Sciences (P01 ES006052); National Cancer Institute (R01 CA093780)
Based on 5 listed funder(s).
Publication
- Published
- 2011-03-01 · Cancer Prev Res (Phila) · vol. 4 · issue 3 · pp. 384–395
- Publisher
- American Association for Cancer Research
- Cited
- 207 citations · more than 98% of similar papers · 6.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 47 works
- Access
- Free to read
- Research areas
- Genomics, phytochemicals, and oxidative stress · Bioactive Compounds and Antitumor Agents
- Keywords
- Sulforaphane, Glucoraphanin, Bioavailability, Glucosinolate, Myrosinase, Dosing, Tolerability, Raphanus, Food science, Excretion, Brassica, Chemistry, Animal science, Medicine, Pharmacology, Toxicology, Adverse effect, Biochemistry, Botany, Biology
- MeSH
- humans, brassica, raphanus, oximes, thiocyanates, imidoesters, isothiocyanates, sulfhydryl compounds, sulfoxides, glycoside hydrolases, glucosinolates, anticarcinogenic agents, treatment outcome, cross-over studies, reproducibility of results, signal transduction, biological availability, genotype, beverages, adult, aged, middle aged, china, female, male
22 authors
From US, GB, CN
- Patricia A. EgnerJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jianguo ChenJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jin Bing WangJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yan WuJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yan SunJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jian LuJohns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
Abstract
One of several challenges in design of clinical chemoprevention trials is the selection of the dose, formulation, and dose schedule of the intervention agent. Therefore, a cross-over clinical trial was undertaken to compare the bioavailability and tolerability of sulforaphane from two of broccoli sprout-derived beverages: one glucoraphanin-rich (GRR) and the other sulforaphane-rich (SFR). Sulforaphane was generated from glucoraphanin contained in GRR by gut microflora or formed by treatment of GRR with myrosinase from daikon (Raphanus sativus) sprouts to provide SFR. Fifty healthy, eligible participants were requested to refrain from crucifer consumption and randomized into two treatment arms. The study design was as follows: 5-day run-in period, 7-day administration of beverages, 5-day washout period, and 7-day administration of the opposite intervention. Isotope dilution mass spectrometry was used to measure levels of glucoraphanin, sulforaphane, and sulforaphane thiol conjugates in urine samples collected daily throughout the study. Bioavailability, as measured by urinary excretion of sulforaphane and its metabolites (in approximately 12-hour collections after dosing), was substantially greater with the SFR (mean = 70%) than with GRR (mean = 5%) beverages. Interindividual variability in excretion was considerably lower with SFR than with GRR beverage. Elimination rates were considerably slower with GRR, allowing for achievement of steady-state dosing as opposed to bolus dosing with SFR. Optimal dosing formulations in future studies should consider blends of sulforaphane and glucoraphanin as SFR and GRR mixtures to achieve peak concentrations for activation of some targets and prolonged inhibition of others implicated in the protective actions of sulforaphane. Cancer Prev Res; 4(3); 384-95. ©2011 AACR.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.